DGAP-News
340
0 Kommentare
MeVis Medical Solutions AG: MeVis Q1 2015: Mixed first quarter
340 
0 KommentareDGAP-News: MeVis Medical Solutions AG / Key word(s): Quarter
Results/Interim Report
MeVis Medical Solutions AG: MeVis Q1 2015: Mixed first quarter
21.05.2015 / 10:19
---------------------------------------------------------------------
Very positive sales by strong US Dollar, declining results
- Sales in the first quarter increased by 21 % to EUR 3.4 m due to the
strong US dollar (previous year: EUR 2.8 m)
- Earnings before interest and taxes (EBIT) decreased to EUR 0.5 m
(previous year EUR 0.7 m), EBIT margin of 16 %
- Net profit also declined slightly to EUR 0.7 m (previous year EUR 0.8
m)
- Liquidity of EUR 19.0 m as at March 31, 2015 (Dec. 31, 2014: EUR 17.5
m)
Bremen, May 21, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a
leading provider of medical imaging software, today announced its results
for the first quarter of 2015.
Sales in the first quarter of 2015 came to EUR 3,408 k, 21 % higher than in
the first quarter of 2014 (EUR 2,828 k). Revenues generated from licensing
business increased by 17 % to TEUR 1,561, revenues from maintenance
business increased by 9 % and accounted with TEUR 1,493 for 44 % of total
sales. Sales in the Digital Mammography segment grew by 22 % to EUR 2,721 k
(prev. year: EUR 2,227 k) and sales in the Other Diagnostics segment grew
by 14 % to EUR 687 k (prev. year: EUR 601 k).
Operating expenses increased slightly in the first quarter of 2014. Staff
costs increased by only 1 % to EUR 1,837 k (prev. year: EUR 1,812 k). Other
operating expenses rose by 34 % to EUR 549 k (prev. year: EUR 411 k) driven
by legal and consulting cost.
The capitalization of development expenses was ceased in the fourth quarter
of 2014 (Q1 2014: EUR 428 k).
Due to increased sales and despite higher costs and the cessation of the
capitalization of development expenses, we see a slight increase of the
EBITDA (earnings before interest, taxes, depreciation and amortization) by
1 %, from EUR 1,100 k to EUR 1,107 k.
After depreciation and amortization of EUR 565 k (up 39 % year on year),
EBIT (earnings before interest and taxes) declined considerably by 22 % to
EUR 542 k (prev. year: EUR 694 k) corresponding to an EBIT margin of 16 %
(prev. year: 25 %).
The net financial result improved by EUR 59 k to EUR 138 k year on year.
Mainly the development of the US$ exchange rate, the continuous improvement
of the MeVis BreastCare, and the interest result have contributed to this.
Income tax expenses decreased by EUR 46 k to EUR 42 k.
Net profit fell by EUR 47 k to EUR 683 k, which is equivalent to earnings
per share of EUR 0,37 (prev. year: 0,40).
Cash and cash equivalents increased by EUR 1.453 k to EUR 18.964 k as of
March 31, 2015 compared to the end of 2014.
The Company's financial reports can be downloaded from the following
website:
http://www.mevis.de/en/investor-relations/financial-reports/
---------------------------------------------------------------------
21.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
360419 21.05.2015
Very positive sales by strong US Dollar, declining results
- Sales in the first quarter increased by 21 % to EUR 3.4 m due to the
strong US dollar (previous year: EUR 2.8 m)
- Earnings before interest and taxes (EBIT) decreased to EUR 0.5 m
(previous year EUR 0.7 m), EBIT margin of 16 %
- Net profit also declined slightly to EUR 0.7 m (previous year EUR 0.8
m)
- Liquidity of EUR 19.0 m as at March 31, 2015 (Dec. 31, 2014: EUR 17.5
m)
Bremen, May 21, 2015 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a
leading provider of medical imaging software, today announced its results
for the first quarter of 2015.
Sales in the first quarter of 2015 came to EUR 3,408 k, 21 % higher than in
the first quarter of 2014 (EUR 2,828 k). Revenues generated from licensing
business increased by 17 % to TEUR 1,561, revenues from maintenance
business increased by 9 % and accounted with TEUR 1,493 for 44 % of total
sales. Sales in the Digital Mammography segment grew by 22 % to EUR 2,721 k
(prev. year: EUR 2,227 k) and sales in the Other Diagnostics segment grew
by 14 % to EUR 687 k (prev. year: EUR 601 k).
Operating expenses increased slightly in the first quarter of 2014. Staff
costs increased by only 1 % to EUR 1,837 k (prev. year: EUR 1,812 k). Other
operating expenses rose by 34 % to EUR 549 k (prev. year: EUR 411 k) driven
by legal and consulting cost.
The capitalization of development expenses was ceased in the fourth quarter
of 2014 (Q1 2014: EUR 428 k).
Due to increased sales and despite higher costs and the cessation of the
capitalization of development expenses, we see a slight increase of the
EBITDA (earnings before interest, taxes, depreciation and amortization) by
1 %, from EUR 1,100 k to EUR 1,107 k.
After depreciation and amortization of EUR 565 k (up 39 % year on year),
EBIT (earnings before interest and taxes) declined considerably by 22 % to
EUR 542 k (prev. year: EUR 694 k) corresponding to an EBIT margin of 16 %
(prev. year: 25 %).
The net financial result improved by EUR 59 k to EUR 138 k year on year.
Mainly the development of the US$ exchange rate, the continuous improvement
of the MeVis BreastCare, and the interest result have contributed to this.
Income tax expenses decreased by EUR 46 k to EUR 42 k.
Net profit fell by EUR 47 k to EUR 683 k, which is equivalent to earnings
per share of EUR 0,37 (prev. year: 0,40).
Cash and cash equivalents increased by EUR 1.453 k to EUR 18.964 k as of
March 31, 2015 compared to the end of 2014.
The Company's financial reports can be downloaded from the following
website:
http://www.mevis.de/en/investor-relations/financial-reports/
---------------------------------------------------------------------
21.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
360419 21.05.2015
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Auch bei Lesern beliebt
